GlassScriptPhysician profile
Audrey Renee Smith
NPI 1538514567
$12,223.02
in general payments reported to CMS, 2019-2025
51 companies · $2,492 in 2025
The $2,492 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $1,028 · 2021: $1,731 · 2022: $1,885 · 2023: $2,050 · 2024: $2,540 · 2025: $2,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,063 · Entertainment: $19.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,063.44 |
| Entertainment | $19.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,090.08 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,866.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,210.07 | 2020-2025 | Mounjaro, Emgality, Zepbound |
| Pfizer INC. | $1,098.63 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $914.98 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $636.83 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.47 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $316.74 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $314.92 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $262.60 | 2022-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $248.50 | 2019-2023 | Livalo, Seglentis |
| Shield Therapeutics INC | $248.35 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $228.63 | 2022 | |
| Axsome Therapeutics, INC. | $223.35 | 2025 | Auvelity |
| Mylan Specialty L.P. | $188.06 | 2019-2023 | Yupelri |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.